Articles tagged with: Doxorubicin Liposomal
News»
Yesterday was the second day of the 2012 American Society of Hematology (ASH) annual meeting. Although the myeloma-related sessions got a bit of a late start, the day featured a wide range of interesting presentations about multiple myeloma.
Many myeloma-related oral presentations were given in the afternoon and were summarized in updates published yesterday and earlier today.
During the evening yesterday, a poster session took place where important new research findings were summarized in posters displayed throughout a large conference hall. The studies covered a variety of myeloma-related topics, ranging …
NewsFlash »
J&J Restores Full Access To Doxil – Johnson & Johnson announced last week that the company has restored full access to a reliable supply of Doxil (doxorubicin liposomal), which is approved in combination with Velcade (bortezomib) for previously treated multiple myeloma patients. Doxil has been in short supply since August 2011 after the company had announced delays in manufacturing a month earlier. Johnson & Johnson also announced last week that it will be suspending its Doxil CARES Physician Access Program, which it had created in response to the temporary Doxil shortage. For more information, please see the Doxil Supply website.
Study Shows No Link Between Tobacco Smoking And Multiple Myeloma – Results of a recent Greek analysis indicate that tobacco smoking does not increase the risk of developing multiple myeloma. The Greek researchers point out that their findings apply to both current and former smokers. The analysis was based on 40 studies, which included a total of approximately two million people. For more information, please see the study in The International Journal of Cancer (abstract).
Physical Activity Declines After Myeloma Diagnosis – Results of an Australian study show that levels of physical activity decline after people are diagnosed with multiple myeloma. The researchers identified fatigue, injuries, and pain as the strongest perceived barriers to participation in physical activity. However, they also found that 41 percent of patients were willing to participate in an exercise program if one was offered to them. Based on their findings, the researchers recommended that measures to increase physical activity should aim to decrease the perceived barriers. For more information, please see the study in Supportive Care in Cancer (pdf).
LLS Teleconference On Myeloma Diagnosis And Treatment – On October 30, the Leukemia & Lymphoma Society (LLS) will sponsor a free teleconference call entitled “Myeloma Diagnosis and Treatment Update.” The call will begin at 12:30 p.m. Eastern Time and will be led by Dr. Ruben Niesvizky from the Weill Medical College of Cornell University in New York City. Dr. Niesvizky will speak about the goals of myeloma treatment, current treatments and emerging therapies, management of side effects, and the importance of patient and health care team communications. After the talk, Dr. Niesvizky will answer questions from participants. For more information or to register, please see the LLS website.
News»
Results of a small Phase 2 study show that the four-drug combination therapy of Revlimid, Velcade, Doxil, and dexamethasone may be an effective and tolerable treatment option for relapsed and refractory multiple myeloma patients.
According to the study investigators, the four-drug regimen compares favorably to the three-drug combination without Revlimid in that it improves response rates without a significant increase in side effects.
The investigators recommend that future trials further investigate the number and specific types of previous treatments to identify those in which the Revlimid, Velcade, Doxil, and dexamethasone combination may …
News»
European researchers found that the addition of Doxil to Velcade significantly extends the time to disease progression in relapsed / refractory multiple myeloma patients, regardless of age, number of previous therapies, disease stage, and resistance to previous therapy.
However, the addition of Doxil increased the rate of side effects in all patients. Despite the increased rate of side effects, the researchers suggested that Velcade plus Doxil should be considered as an additional standard of care option for myeloma patients, especially those with high-risk disease.
In the last decade, the introduction of novel …
News»
Newly diagnosed, high-risk multiple myeloma patients can be effectively treated with sequential therapy, according to the results of a recent Phase 2 study. Participants in this study initially received a combination of Velcade, Doxil, and dexamethasone followed by a combination of thalidomide and dexamethasone, with the potential addition of Velcade to the second phase.
The study authors found that the sequential treatment provided rapid responses, which they said is crucial for patients with organ damage or those with advanced disease who need to quickly proceed to stem cell transplantation.
They suggested that …
NewsFlash »
Dr. Ken Shain Joins The Beacon's Medical Advisor Team – Dr. Ken Shain, an assistant professor of hematologic malignancies at the H. Lee Moffitt Cancer Center in Tampa, FL, has joined The Myeloma Beacon's team of Medical Advisors. Beacon Medical Advisors assist with answering medical questions posted in the Beacon’s multiple myeloma forums. For more information about getting medical questions answered in the forums, please see these instructions.
Onyx And MMRF Offer Carfilzomib Expanded Access Program For Myeloma Patients – Onyx Pharmaceuticals and the Multiple Myeloma Research Foundation (MMRF) announced last week that they have created the Carfilzomib Myeloma Access Program (C-MAP), which will make carfilzomib available to relapsed/refractory multiple myeloma patients in the United States who do not have any treatment alternatives. Carfilzomib is currently being investigated as a treatment for multiple myeloma. The drug is not yet approved for use in the U.S.; however, under its expanded access program, the U.S. Food and Drug Administration allows ill patients who lack any other treatment options to try a promising drug that is still under development. For more information, please see the Onyx C-MAP website.
Janssen Launches Physician Access Program For Doxil – Janssen Products, the manufacturer of Doxil (doxorubicin liposomal), announced on Friday that, in response to a temporary shortage of Doxil, the company has established the Doxil C.A.R.E.S. Physician Access Program. This program will allocate any newly available Doxil supply to physicians who are treating patients currently on the drug. The goal of the program is to ensure that patients currently on Doxil receive their medication. Janssen announced manufacturing delays last month that resulted in a temporary shortage of the drug. Doxil is currently approved in combination with Velcade (bortezomib) for previously treated multiple myeloma patients. For more information, please see the Doxil website.
NewsFlash »
J&J Announces Shortage Of Doxil – Johnson & Johnson announced manufacturing delays last week that will result in a temporary shortage of Doxil (doxorubicin liposomal), which is approved in combination with Velcade (bortezomib) for previously treated multiple myeloma patients. The company is estimating that shipments of Doxil will resume in late August and asked physicians not to start any new patients on Doxil until then. Last month, the company informed doctors about the potential shortage so physicians could discuss treatment options with their patients who might be affected by the shortage. For more information, see the Johnson & Johnson announcement about the shortage. Updates on the situation will be available on the Doxil website.
Children Raise $8.4 Million In Spare Change To Support LLS – Students across the United States recently raised $8.4 million for the Leukemia & Lymphoma Society (LLS) to fund research for blood cancers, including multiple myeloma, as well as provide services and support for blood cancer patients. The students put collection jars in their classrooms and collected spare change over a three-week period during this past school year. The top fundraising class at each school received a pasta party from Olive Garden. Over the past 17 years, this program has raised more than $61 million for the LLS. For more information, see the Olive Garden press release.
Multiple Myeloma Educational Program – An educational program for multiple myeloma patients will be held on August 6 in Richmond, VA. A physician specializing in multiple myeloma will talk about treatment options for myeloma patients as well as answer attendee’s questions. A multiple myeloma patient will also speak about his experiences. Registration will begin at 9:30 a.m., and the program will start at 10 a.m. at the Westin Richmond. The event is sponsored by Millennium, the manufacturer of Velcade. For more information, see the Beacon event description or call 1-866-508-6181.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
